Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Balzarini J, Pérez-Pérez MJ, San-Félix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ, De Clercq E. Balzarini J, et al. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4392-6. doi: 10.1073/pnas.89.10.4392. Proc Natl Acad Sci U S A. 1992. PMID: 1374900 Free PMC article.
Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ, De Clercq E. Balzarini J, et al. J Biol Chem. 1992 Jun 15;267(17):11831-8. J Biol Chem. 1992. PMID: 1376314 Free article.
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1.
Balzarini J, Pérez-Pérez MJ, San-Félix A, Velazquez S, Camarasa MJ, De Clercq E. Balzarini J, et al. Antimicrob Agents Chemother. 1992 May;36(5):1073-80. doi: 10.1128/AAC.36.5.1073. Antimicrob Agents Chemother. 1992. PMID: 1510396 Free PMC article.
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
Balzarini J, Pérez-Pérez MJ, Vélazquez S, San-Félix A, Camarasa MJ, De Clercq E, Karlsson A. Balzarini J, et al. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5470-4. doi: 10.1073/pnas.92.12.5470. Proc Natl Acad Sci U S A. 1995. PMID: 7539917 Free PMC article.
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J, Karlsson A, Vandamme AM, Pérez-Pérez MJ, Zhang H, Vrang L, Oberg B, Bäckbro K, Unge T, San-Félix A, et al. Balzarini J, et al. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6952-6. doi: 10.1073/pnas.90.15.6952. Proc Natl Acad Sci U S A. 1993. PMID: 7688467 Free PMC article.
115 results